COPD Clinical Trial
Official title:
Comparison of Bronchodilator Efficacy of Tiotropium/Formoterol Combination Treatment Administered (qd) Via Discair® With Tiotropium (qd) Monotherapy or Tiotropium (qd) + Formoterol (Bid) Free Combination Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The overall objective is to asses the bronchodilator effect of once daily
Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.)
monotherapy delivered via Handihaler and tiotropium (q.d.) delivered via Handihaler +
formoterol (b.i.d) delivered via Aerolizer free combination treatment in patients with stable
moderate to severe COPD.
Spirometric measurements (FEV1, FVC) will be performed for a period of 24 h at 12 different
times: pre-treatment (15 min prior to the first dose) and post-treatment (30. min, 60 min [1
hr], 120 min [2 hr], 180 min [3 hr], 240 min [4 hr], 360 min [6 hr], 480 min [8 hr], 600 min
[10 hr], 720 min [12 hr], 840 min [14 hr],1440 min [24 hr].
The overall objective is to asses the bronchodilator effect of once daily
Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.)
monotherapy delivered via Handihaler and tiotropium (q.d.) delivered via Handihaler +
formoterol (b.i.d) delivered via Aerolizer free combination treatment in patients with stable
moderate to severe COPD.
Patients will be randomly assigned to receive Tiotropium/Formoterol combination as dry powder
for inhalation by Discair® (test inhaler, n = 29) or Tiotropium as dry powder capsule for
inhalation by HandiHaler or tiotropium dry powder capsule for inhalation by HandiHaler +
formoterol as dry powder capsule for inhalation by Aerolizer. Patients will be evaluated at 4
consecutive visits: baseline (enrollment), screening, treatment, and 24h after treatment.
For newly diagnosed and formerly diagnosed patients who are not on COPD medication, the
screening visit will be performed on the day of enrollment. For formerly diagnosed patients
receiving COPD treatment, the day of the screening visit will be based on the completion of a
run-in period, with the length determined by the specific medication. During the run-in
period, salbutamol (100 µg inhaler) will be prescribed as a rescue medication.
Spirometric measurements (FEV1, FVC) will be performed for a period of 24 h at 12 different
times: pre-treatment (15 min prior to the first dose) and post-treatment (30. min, 60 min [1
hr], 120 min [2 hr], 180 min [3 hr], 240 min [4 hr], 360 min [6 hr], 480 min [8 hr], 600 min
[10 hr], 720 min [12 hr], 840 min [14 hr],1440 min [24 hr].
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
| Completed |
NCT04105075 -
COPD in Obese Patients
|
||
| Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
| Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
| Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
| Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
| Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
| Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
| Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
| Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
| Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
| Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
| Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
| Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
| Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |